Skip to main content
All lobbying filings

TENAGRITY SOLUTIONS, LLC

Lobbying for 1DAY SOONER ACTION PROJECT · advocacy organization supporting medical research

 Filing 2nd Quarter - Report
Reporting period
2nd Quarter 2025
Apr 1 - June 30 · Posted Jul 21, 2025
Income
$30,000.00
What the client paid this registrant for the period.
Client based in
Delaware

Official filing document

 Lobbyists on this filing 1
  • JENNY CAROLINE DEBERRY
    Previously held: Senior Legislative Assistant/ Legislative Assistant, Congressman John J. Duncan, Jr.; Senior Campaign Finance Analyst/ Campaign Finance Analyst, Federal Election Commission

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

 Government bodies contacted 4
  • Defense, Dept of (DOD)
  • Health & Human Services, Dept of (HHS)
  • HOUSE OF REPRESENTATIVES
  • SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

 Bills named in this filing 3
  • S 2256
    Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
  • HR 4121
    Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
  • S 2296
    National Defense Authorization Act for Fiscal Year 2026
 Lobbying activity 6
Health Issues

Pandemic and All-Hazards Preparedness and Response Act (PAHPA) and Prescription Drug User Fee Act (PDUFA) and House and Senate FY26 Ag-FDA (S.2256, H.R. 4121), L-HHS appropriations bills (and report language) to ensure: adequate resources for HHS and interagency / interdepartmental relationships for emerging pathogen and pandemic preparedness; prioritization of improved indoor air quality in military and other federal facilities to promote health (additional legislation on this topic: NDAA); FDA reforms including maximized use of AI (pursuit of related congressional support letters as well). Support for Sen. Cassidy's anticipated HEP-C elimination legislation (including specifically clinical trial research). Communication with congressional offices re: enabling greater use of human challenge studies. Discussions with House and Senate offices about potential new legislation related to how the government encourages innovation in health care and other industries.

Medical/Disease Research/Clinical Labs

Pandemic and All-Hazards Preparedness and Response Act (PAHPA) and Prescription Drug User Fee Act (PDUFA) and House and Senate FY26 Ag-FDA (S.2256, H.R. 4121), L-HHS appropriations bills (and report language) to ensure: adequate resources for HHS and interagency / interdepartmental relationships for emerging pathogen and pandemic preparedness; prioritization of improved indoor air quality in military and other federal facilities to promote health (additional legislation on this topic: NDAA); FDA reforms including maximized use of AI (pursuit of related congressional support letters as well). Support for Sen. Cassidy's anticipated HEP-C elimination legislation (including specifically clinical trial research). Communication with congressional offices re: enabling greater use of human challenge studies. Discussions with House and Senate offices about potential new legislation related to how the government encourages innovation in health care and other industries.

Medicare/Medicaid

House and Senate FY26 appropriations bills (L-HHS) to ensure: adequate resources for HHS and interagency / interdepartmental relationships for emerging pathogen and pandemic preparedness; prioritization of improved indoor air quality in military and other federal facilities to promote health

Defense

Pandemic and All-Hazards Preparedness and Response Act (PAHPA) and Prescription Drug User Fee Act (PDUFA) and House and Senate FY26 Ag-FDA (S.2256, H.R. 4121), L-HHS appropriations bills (and report language) to ensure: adequate resources for HHS and interagency / interdepartmental relationships for emerging pathogen and pandemic preparedness; prioritization of improved indoor air quality in military and other federal facilities to promote health (additional legislation on this topic: NDAA); FDA reforms including maximized use of AI (pursuit of related congressional support letters as well). Support for Sen. Cassidy's anticipated HEP-C elimination legislation (including specifically clinical trial research). Communication with congressional offices re: enabling greater use of human challenge studies. Discussions with House and Senate offices about potential new legislation related to how the government encourages innovation in health care and other industries. Discussions with the HHS and DoD to support the FDA - DoD relationship to prioritize the development of safe and effective medical products that could save military personnel lives

Budget/Appropriations

House and Senate FY26 appropriations bills (Ag-FDA: S.2256, H.R. 4121) and NDAA S. 2296 (and report language) to ensure: adequate resources for HHS and interagency / interdepartmental relationships for emerging pathogen and pandemic preparedness; prioritization of improved indoor air quality in military and other federal facilities to promote health

Clean Air and Water (quality)

House and Senate FY26 appropriations bills (Ag-FDA: S.2256, H.R. 4121) and NDAA S. 2296 (and report language) to ensure: adequate resources for HHS and interagency / interdepartmental relationships for emerging pathogen and pandemic preparedness; prioritization of improved indoor air quality in military and other federal facilities to promote health

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem